September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
6 citations
,
September 2014 in “Cutaneous and ocular toxicology” Acitretin can cause eyebrow and eyelash hair loss.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
22 citations
,
October 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Combining isotretinoin and dapsone effectively treated a challenging scalp condition.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
December 2024 in “Medicina (Ribeirão Preto)” Adverse reactions to isotretinoin in acne treatment are common and mainly linked to treatment duration.
December 2025 in “Journal of the European Academy of Dermatology and Venereology”
232 citations
,
June 1975 in “Journal of Steroid Biochemistry” Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
November 2023 in “Frontiers in pharmacology” Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
9 citations
,
October 1993 in “The Journal of Clinical Pharmacology” Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
6 citations
,
April 2018 in “Transplantation proceedings” A woman experienced severe side effects from a drug due to a specific genetic variation, suggesting genetic testing could prevent such risks.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
12 citations
,
May 2020 in “Dermatology and therapy” A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.
2 citations
,
June 2022 in “Journal of cosmetic dermatology” Dupilumab can help hair regrowth but may also trigger alopecia areata.
13 citations
,
January 1997 in “Biochemical Pharmacology” Human liver enzyme DHEA ST helps process minoxidil.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
23 citations
,
October 2005 in “Journal of The American Academy of Dermatology” Two transplant patients on cyclosporine unexpectedly developed hair loss.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
March 2020 in “Hair transplant forum international” Taking minoxidil by mouth for hair growth might not be safe if you also take aspirin.
May 2025 in “Reactions Weekly” 3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.